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Summary
 
The complex pathophysiology of lung allergic inflammation and bronchial hyperresponsiveness
(BHR) that characterize asthma is achieved by the regulated accumulation and activation of
different leukocyte subsets in the lung. The development and maintenance of these processes
correlate with the coordinated production of chemokines. Here, we have assessed the role that
different chemokines play in lung allergic inflammation and BHR by blocking their activities
in vivo. Our results show that blockage of each one of these chemokines reduces both lung
leukocyte infiltration and BHR in a substantially different way. Thus, eotaxin neutralization re-
duces specifically BHR and lung eosinophilia transiently after each antigen exposure. Mono-
cyte chemoattractant protein (MCP)-5 neutralization abolishes BHR not by affecting the accu-
mulation of inflammatory leukocytes in the airways, but rather by altering the trafficking of the
eosinophils and other leukocytes through the lung interstitium. Neutralization of RANTES
(regulated upon activation, normal T cell expressed and secreted) receptor(s) with a receptor
antagonist decreases significantly lymphocyte and eosinophil infiltration as well as mRNA expres-
sion of eotaxin and RANTES. In contrast, neutralization of one of the ligands for RANTES re-
ceptors, macrophage-inflammatory protein 1
 
a
 
, reduces only slightly lung eosinophilia and BHR.
Finally, MCP-1 neutralization diminishes drastically BHR and inflammation, and this correlates
with a pronounced decrease in monocyte- and lymphocyte-derived inflammatory mediators.
These results suggest that different chemokines activate different cellular and molecular pathways
that in a coordinated fashion contribute to the complex pathophysiology of asthma, and that their
individual blockage results in intervention at different levels of these processes.
Key words: chemokines • allergic inflammation • bronchial hyperresponsiveness • 
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ung inflammation and bronchial hyperreactivity (BHR)
 
1
 
are two distinct characteristics of asthma (1, 2). Eosino-
phils are considered to be the central proinflammatory leu-
kocyte involved in the asthmatic reaction, due in part to se-
creted toxic granular proteins and membrane products that
induce pulmonary damage and subsequently intensify
BHR (1–3). Moreover, there is a correlation between lev-
els of eosinophil-derived cation proteins in the airways of
asthmatic patients and the severity of this disease (2). De-
spite the fact that the eosinophil is the predominant infil-
trating cell type during asthma, other leukocytes may be
critical in the initiation and amplification of the inflamma-
tory response (4, 5). The prevention of both lung eosino-
philia and BHR in T lymphocyte–deficient mice during
antigen-induced inflammation supports a critical role for T
cell cytokines such as IL-4 and IL-5 (6–9). The role that
 
1
 
Abbreviations used in this paper:
 
 BAL, bronchoalveolar lavage; BHR, bron-
chial hyperresponsiveness; Eot, eotaxin; LT, leukotriene; MCP, mono-
cyte chemoattractant protein; Met-RANTES, methionylated RANTES;
MIP, macrophage-inflammatory protein; OVA, ovalbumin; RANTES,
regulated upon activation, normal T cell expressed and secreted; RPA,
RNase protection assay; TX, thromboxane.
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monocytes/macrophages play in lung allergic inflammation
pertains to their ability to act as APCs and to generate a va-
riety of mediators that promote both eosinophil activation
and adhesion to endothelium (10). In this regard, macro-
phages secrete eosinophilic chemoattractants, including leu-
kotriene (LT)B
 
4
 
, platelet-activating factor, and C5a, in ad-
dition to modulating the generation of some of these
factors by eosinophils (10–12).
The immunological characterization of lung eosinophilia
implicates chemokines in the initiation of lung allergic in-
flammation and the subsequent development of BHR (5,
13–17). Chemokines are a group of cytokines that promote
leukocyte recruitment to inflammatory sites, stimulate leu-
kocyte exocytosis, and induce hematopoiesis (18–20).
Chemokine expression is high and readily modulated in the
lung during the development of an inflammatory response
(5, 16, 17). Among these, RANTES (regulated upon acti-
vation, normal T cell expressed and secreted), monocyte
chemoattractant protein (MCP)-5, and eotaxin have been
shown to induce eosinophil migration in vitro and/or to be
involved in lung eosinophilia in humans, guinea pigs, and
mice (5, 16, 13, 21–23). In addition to their activity on
eosinophils, RANTES and MCP-5 are strong chemotactic
factors both in vivo and in vitro for T lymphocytes and
monocytes, respectively (16, 24). MCP-1, which is primar-
ily involved in the recruitment of mononuclear phagocytes
(25), is also strongly expressed in the lung during inflam-
mation (5, 26). Signaling mediated by this noneosinophilic
chemokine might also be involved in macrophage activa-
tion leading to a cascade of proinflammatory and tissue
damage events (27).
In this report, we have used a mouse model of asthma in
which the expression of the chemokines eotaxin, RANTES,
macrophage-inflammatory protein (MIP)-1
 
a
 
, MCP-5, and
MCP-1 is clearly modulated during disease progression (5).
To understand the pathophysiology that results from the
expression of multiple chemokines with partially overlap-
ping functions, we have analyzed (
 
a
 
) the direct recruitment
of specific cell types to the lung interstitium and airways
exerted by these chemokines, (
 
b
 
) their role in the induction
of BHR, (
 
c
 
) the effect they exert on the gene expression of
other chemokines, and (
 
d
 
) the modulation by these
chemokines of different components of the pathological re-
sponse, such as cell activation or inflammatory mediator
production.
 
Materials and Methods
 
Mice and In Vivo Procedures.
 
8–10-wk-old C57BL/6J mice
were purchased from The Jackson Laboratory (Bar Harbor, ME)
and kept in the specific pathogen–free mouse facility at Millen-
nium Pharmaceuticals, Inc. The mouse model of lung inflamma-
tion used here consists of a sensitization phase (ovalbumin
[OVA], 0.1 mg/mouse intraperitoneally on day 0; Sigma Chemi-
cal Co., St. Louis, MO) and an induction of the response phase
(2% OVA for 5 min intranasally on day 8, and 1% OVA for 20
min intranasally on days 15–21). PBS (intraperitoneal and/or in-
tranasal) was administered to mice as a negative control. For the
blocking experiments, mice also received 20 
 
m
 
g/mouse of neu-
tralizing polyclonal Abs against either eotaxin (anti-Eot), MCP-5
(anti–MCP-5), MIP-1
 
a
 
 (anti–MIP-1
 
a
 
), or 5 
 
m
 
g/mouse of mAb
against MCP-1/JE (anti–MCP-1/JE), or 25 
 
m
 
g/mouse of the
RANTES antagonist, methionylated (Met)-RANTES. Anti–
MIP-1
 
a
 
 (R&D Systems, Inc., Minneapolis, MN) was selected for
its ability to neutralize the in vitro bioactivity of recombinant
murine MIP-1
 
a
 
 and was used at the manufacturer’s recom-
mended dose. Anti-Eot Ab blocked the in vitro transmigration of
eosinophils to eotaxin by 97% (5). Similarly, anti–MCP-5 Ab
blocked MCP-5–induced eosinophil migration in vitro by 99%
(16). The anti–MCP-1/JE Ab also showed a dose-dependent in-
hibition of MCP-1 bioactivity using in vitro chemotactic assays
on monocytes (28). We have determined previously that the dose
of antibodies used here blocked 100% of migration to each partic-
ular chemokine during in vivo peritoneal migration assays (data
not shown) or during crescentic nephritis (29). Met-RANTES
has been shown to inhibit both in vitro chemotaxis and calcium
influx on the THP-1 cell line and T cells in response to
RANTES and MIP-1
 
a
 
 (30) and in vivo inflammation (29).
These antibodies were administered intravenously 30 min before
OVA provocation on days 8–21. In another series of blocking ex-
periments, anti–MCP-1/JE mAb, anti-Eot, or anti–MCP-5 poly-
clonal Abs were also administered on days 8–16, days 15–21, days
19–21, or day 21. OVA-treated control mice were injected with
the same amount of control Ab at the same time points indicated
during treatment. Rabbit Ig fraction (DAKO Corp., Santa Bar-
bara, CA) was used as control for poly-Eot and poly–MCP-5,
normal hamster IgG (Jackson ImmunoResearch Labs, West
Grove, PA) was used as control for anti–MCP-1/JE, and PBS as
control for Met-RANTES. 1 or 3 h after OVA administration on
day 15 or 21, mice were killed by CO
 
2
 
 asphyxiation and ana-
lyzed.
Bronchoalveolar lavage (BAL) was performed as described
(23). In brief, the airways of the mice were lavaged via a trachea
cannula with 1 ml of PBS. The resulting BAL fluid was immedi-
ately centrifuged (700 
 
g
 
, 5 min, 4
 
8
 
C), and BAL cells were then
washed and resuspended in 1 ml of PBS.
The degree of bronchoconstriction (BHR) was measured 3 h
after the last antigen challenge by recording respiratory pressure
curves by whole body plethysmography (Buxco Electronics, Inc.,
Sharon, CT) in response to inhaled methacholine (MCh; Aldrich
Chemical Co., Milwaukee, WI) at a concentration of 3 
 
3
 
 10
 
2
 
2
 
 M
for 1 min, as described previously (3, 31). BHR was expressed as
enhanced pause (
 
Penh
 
), a calculated value, which correlates with
measurement of airway resistance, impedance, and intrapleural
pressure in the same mouse. 
 
Penh
 
 
 
5
 
 (
 
Te
 
/
 
Tr
 
 
 
2
 
 1) 
 
3
 
 (
 
Pef
 
/
 
Pif
 
),
where 
 
Te
 
 is expiration time; 
 
Tr
 
, relaxation time; 
 
Pef
 
, peak expira-
tory flow; and 
 
Pif
 
, peak inspiratory flow 
 
3
 
 0.67 coefficient (32).
The relaxation time is the time it takes for the box pressure to
change from a maximum to a user-defined percentage of the
maximum. Here, 
 
Tr
 
 measurement begins at the maximum box
pressure and ends at 40%.
 
Immunohistochemical Phenotyping and Quantitation of Leuko-
cytes.
 
Total BAL cell counts were performed, and aliquots (5 
 
3
 
 10
 
5
 
cells/slide) were pelleted onto glass slides by cytocentrifugation.
To determine the number of eosinophils and neutrophils, slides
were stained with Wright-Giemsa (Fisher Scientific Co., Pitts-
burgh, PA). T lymphocytes, B lymphocytes, and mononuclear
phagocytes were identified by Thy 1.2 (53-2.1; PharMingen, San
Diego, CA), IgM (II/41; PharMingen), and Moma-2 (Biosource
International, Camarillo, CA) staining, respectively, as described
(5). Percentage of eosinophils, lymphocytes, neutrophils, and
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macrophages was determined by counting their number in eight
high power fields (
 
3
 
40, total area 0.5 mm
 
2
 
) per area randomly
selected, and dividing this number by the total number of cells
per high power field. To obtain the absolute number of each leu-
kocyte subtype in the lavage, these percentages were multiplied
by the total number of cells recovered from the BAL fluid.
Lung sections from the different experimental groups of mice
were prepared as described (5). In brief, lungs were fixed in 10%
neutral buffered formalin (NBF; J.T. Baker, Phillipsburg, NJ) and
paraffin embedded. Sections (4 microns) were cut onto micro-
scope slides and stained with hematoxylin/eosin according to
standard protocols. To determine the sizes of pulmonary infil-
trates in the experimental groups of mice, the area of lung tissue
covered by infiltrate was calculated in sections at low power
(
 
3
 
100) using NIH Image 1.56. At least six fields of at least 0.01
mm
 
2
 
 were scanned, and the mean percentage area was deter-
mined for each mouse of each experimental group, relative to the
control mice for each experiment.
 
Determination of Chemokine Protein Expression within Lung Tissue.
 
The level of expression of eotaxin protein and MCP-5 protein
was determined in sections from lungs of OVA-treated mice and
controls. Sections were fixed and stained using a modified avidin/
biotin staining method. All incubations were carried out under
humidified conditions, and slides were washed twice between
steps for 5 min each in 0.1 M PBS supplemented with 0.2% gela-
tin. Sections were overlaid with 20% normal rabbit serum in PBS
for 15 min and then incubated overnight at 4
 
8
 
C with either mon-
oclonal anti-Eot diluted 1:2 in PBS with 0.1% BSA and 0.1% so-
dium azide (5) or anti-murine MCP-5 (ZY2A11) culture super-
natant (undiluted). Endogenous peroxide was subsequently
blocked by incubation for 20 min in methanol containing 0.3%
hydrogen peroxide. Nonspecific staining due to cross-reaction
with endogenous avidin or biotin was blocked by incubation
with avidin solution followed by biotin solution, both for 20 min.
Bound mAb was visualized by incubation with biotinylated rabbit
anti–rat Ig diluted in 10% normal mouse serum PBS, and then in-
cubated for 1 h each in streptavidin–peroxidase complex prepared
according to the manufacturer’s instructions (both from DAKO
Corp.). Finally, slides were flooded with peroxidase substrate so-
lution (20 mg diaminobenzidine in 10 ml PBS, containing 0.01%
hydrogen peroxide) for 10 min before counterstaining with
hematoxylin. Control slides were either stained with an isotype-
matched negative control Ab instead of primary Ab or biotiny-
lated anti–rat Ig or streptavidin complex were selectively omitted.
 
Measurement of Chemokine mRNA Expression.
 
Total RNA from
the lungs of OVA-treated mice or control littermates at different
time points was extracted by the single step method using RNA
STAT-60 (Tel-Test, Inc., Friendswood, TX).
Chemokine mRNA expression was determined by multiprobe
RNase protection assay (RPA) using the RiboQuant RPA kit
(PharMingen) as recommended by the supplier. The identity and
quantity of each mRNA species in the original RNA sample
were then determined based on the signal intensities given by the
appropriately sized, protected probe fragment bands. The sample
loading was normalized by the housekeeping gene, GAPDH, in-
cluded in each template set.
 
Measurement of Cytokine, Inflammatory Mediator, and Ab Lev-
els.
 
The release of these activating factors during OVA adminis-
tration was determined by ELISA. BAL fluid was taken 1 h after
antigen challenge on day 15 or 21. Serial dilutions of BAL fluid
samples were assayed using commercial ELISA kits for IL-4, IL-5,
TNF-
 
a
 
, and IFN-
 
g
 
 (Endogen, Inc., Boston, MA) and commer-
cial enzyme immunoassay kits for LTB
 
4
 
, PGE
 
2
 
, thromboxane
(TX)B
 
2
 
, and LTC
 
4
 
/D
 
4
 
/E
 
4
 
 (Amersham International, Bucking-
hamshire, UK). Total IgE titers were also measured by ELISA ac-
cording to Ledermann et al. (33). Absorbance values were con-
verted to concentrations of each factor in the BAL fluid
(picograms or nanograms per milliliter) by interpolation in the re-
spective standard curve.
 
Results
 
Neutralization of Specific Chemokines Expressed during
OVA-induced Lung Allergic Inflammation.
 
Mice treated with
OVA (see Materials and Methods; Fig. 1 
 
A
 
, 
 
bottom
 
) show
maximal lung monocyte/macrophage accumulation at
early stages of the inflammatory response (3 h after OVA
challenge on day 15), whereas eosinophil and T lympho-
cyte numbers increase in this organ at late stages of the re-
sponse (3 h after OVA challenge on day 21; Fig. 1 
 
A
 
). The
highest mRNA expression of MCP-1 (day 15, 3 h), as well
as eotaxin and RANTES (day 21, 3 h) and MCP-5 and
MIP-1
 
a
 
 (day 15–21, 3 h), coincides with the kinetics fol-
lowed by the infiltrating leukocytes described above (Fig. 1
 
A
 
; reference 5). No MIP-1
 
b
 
 mRNA expression was de-
tected during OVA treatment (Fig. 1 
 
A
 
). Fig. 1 
 
B
 
 shows
that the production of both eotaxin and MCP-5 protein in
response to OVA correlates with the mRNA expression
pattern shown by these two chemokines, at least at the time
points analyzed (days 15 and 21). In addition, 24 h after
OVA administration on day 21, eotaxin and MCP-5 pro-
tein expression is clearly diminished compared with that
detected 3 h after antigen challenge on the same day (data
not shown). This suggests that the kinetics of chemokine
mRNA expression parallels that observed, at least, for eo-
taxin and MCP-5 protein expression.
To evaluate the specific contribution of eotaxin, an eosi-
nophilic chemokine (13, 22, 23, 34), MCP-5, a monocyte
and eosinophil chemokine (16), MIP-1
 
a
 
, a monocyte,
lymphocyte, and eosinophil chemokine (14, 21, 35), and
MCP-1, a monocyte chemokine (25, 36), to the develop-
ment of lung inflammation in this OVA model, blocking
experiments of these chemokines were performed using
specific neutralizing Abs that have been characterized ex-
tensively in vivo and in vitro (references 5, 16, 28, and 29;
and see Materials and Methods for details). Neutralization
of chemokine receptors that are activated by RANTES, a T
lymphocyte and eosinophil chemokine (21), and other
ligands was achieved using the antagonist Met-RANTES
(see Materials and Methods; reference 30). Neutralizing
agents were delivered daily from days 8 to 21 in these first
series of experiments, and analysis was always performed 3 h
after OVA challenge on day 21. Since the location of infil-
trating cells within the lung correlates strongly with the se-
verity of the inflammatory response (3), leukocyte enumer-
ation was performed in the airways (BAL fluid) and in the
interstitium (lung sections) after OVA treatment.
Eotaxin neutralization during OVA treatment specifi-
cally affected eosinophils both in BAL fluid and pulmonary
interstitium. This effect was more pronounced on day 21
(Fig. 2, and Tables 1 and 2). MCP-5 neutralization during
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OVA treatment strongly affected accumulation of BAL
monocytes and eosinophils on day 15, but not on day 21
(Fig. 2, and Table 1). Interestingly, minimal OVA-induced
leukocyte accumulation was detected in the lung intersti-
tium at any time point after MCP-5 blockage (Table 2, and
Fig. 3). Met-RANTES administration reduced OVA-
induced monocyte accumulation in the BAL by half on day
21 (Table 1) and abrogated BAL lymphocyte and eosino-
phil accumulation during OVA treatment (Fig. 2, and Ta-
ble 1). There was a corresponding decrease in inflammation
in the pulmonary interstitium after Met-RANTES admin-
istration on day 21 (Table 2). MIP-1
 
a
 
 neutralization re-
duced eosinophil recruitment into the airways and pul-
monary interstitium by 20% only at late stages of the
inflammatory response, but without affecting monocyte,
macrophage, and lymphocyte numbers (day 21, Fig. 2 
 
A
 
,
and Tables 1 and 2).
Neutralization of MCP-1 before each intranasal OVA
challenge from days 8 to 21 reduced all four cell popula-
tions that migrate to the lung in response to OVA (Tables 1
and 2, and Fig. 3). Mononuclear phagocyte and eosinophil
accumulation in the lung was reduced by 55 and 80%, re-
spectively, after MCP-1 blockage (Fig. 2, and Table 1).
OVA-induced pulmonary T lymphocyte accumulation
during the inflammatory response was virtually abolished in
the absence of MCP-1–mediated signals (Table 1).
To dissect the windows of action of the chemokines,
blockage experiments were performed at different time
points during OVA treatment, and mice were always ana-
lyzed 3 h after OVA challenge on day 21. Thus, when the
anti–MCP-1 Abs were administered from days 15 to 21,
only a small reduction in the numbers of infiltrating BAL
leukocytes was detected (Fig. 2 
 
C
 
), suggesting a critical role
of MCP-1 at early stages of the inflammatory response.
However, blockage of MCP-1 neither at early stages (days
8–16) nor at late stages of the inflammatory response (days
19–21) is sufficient to decrease significantly BAL leukocyte
 
Figure 1.
 
Chemokine expression and leukocyte infiltration in the lung
of OVA-treated mice. (
 
A
 
) Eotaxin, RANTES, MCP-5, MCP-1, MIP-1
 
a
 
,
and MIP-1
 
b
 
 mRNA expression (
 
gray bars
 
) in the lung of each mouse
were normalized to the 28S rRNA expression in the same organ of the
same mice. The quantitation of total RNA was determined by hybridiza-
tion of a 28S rRNAcDNA probe. Each bar represents data from five mice
at the time points indicated (3 h after OVA challenge on days 15, 18, and
21) during treatment (
 
bottom
 
). Values are expressed as the mean 
 
6
 
 SEM.
The accumulation in the lung of BAL monocytes/macrophages (
 
M/m
 
), T
lymphocytes (
 
L
 
), and eosinophils (
 
E
 
) during OVA treatment (3 h after
antigen challenge on days 15, 18, and 21) is also shown. Although only
BAL accumulation is presented here, there is correlation between these data
and the accumulation in the interstitium (reference 23). Five data points
at the different times indicated were collected per day as described previ-
ously (reference 23). Values are expressed as the mean 
 
6
 
 SEM. 
 
i.n.
 
, intra-
nasal. (
 
B
 
) Immunohistochemical staining of lung sections from OVA-
treated mice on day 15 (3 h; 
 
I 
 
and 
 
III
 
) or day 21 (3 h; 
 
II
 
 and 
 
IV
 
) after OVA
challenge. Sections were stained with anti–MCP-5 mAb (
 
I
 
 and 
 
II
 
; see Ma-
terials and Methods) or anti-Eot mAb (
 
III
 
 and 
 
IV; see Materials and
Methods). Note that positive staining (brown precipitate) is comparable be-
tween days 15 and 21 for MCP-5, but that there is clearly less eotaxin stain-
ing on day 15 compared with day 21. Ig-stained control is also shown (V).
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numbers (Fig. 2 C). No differences in BAL cell numbers
on day 21 were detected after eotaxin blockage for shorter
periods (days 19–21 or day 21) compared with day 8–day
21 blockage (Fig. 2 C). However, when the anti-Eot Abs
were administered on days 8–20 but not on day 21, no re-
duction in BAL eosinophilia was observed (Fig. 2 C). Sig-
nals delivered by MCP-1 during the whole process (days
8–21) are necessary to achieve OVA-induced lung inflam-
mation, whereas eotaxin contributes to the development of
eosinophilia by inducing a daily recruitment of eosinophils
to the lung in this model. On day 21, similar OVA-induced
inflammation was found after day 8–day 21, day 19–day 21,
day 21, or day 8–day 20 MCP-5 blockage (Fig. 2 C).
BHR Induction after Chemokine Blockage. To evaluate whether
the specific reduction in lung inflammation induced by
blockage of a particular chemokine correlates with a de-
crease in airway responsiveness, BHR was evaluated in
OVA-treated mice after chemokine blockage. Fig. 4 A
shows that MIP-1a neutralization reduced BHR by 30%
compared with that observed in OVA-treated controls.
This reduction correlates with the 20–25% decrease in
eosinophil accumulation detected in both lung interstitium
and airways of these mice after anti–MIP-1a Ab adminis-
tration (Fig. 2, and Tables 1 and 2). In addition, eotaxin
neutralization reduced BHR by half compared with that
observed in OVA-treated controls (Fig. 4 A). This reduc-
tion correlates with the 60–70% decrease in eosinophil ac-
cumulation detected in the lung interstitium and airways of
this experimental group of mice (Fig. 2, and Tables 1 and
2). However, when the anti-Eot Abs were administered on
days 8–20 but not on day 21, no reduction in BHR was
observed (Fig. 4 B). In contrast, blockage of eotaxin exclu-
sively at the last day of the treatment (day 21) was sufficient
to reduce BHR by 32% (Fig. 4 B). This indicates that eo-
taxin is involved in the induction of both BAL eosinophilia
(Fig. 2 C) and BHR (Fig. 4 B) after each individual antigen
provocation. The levels of BHR detected at day 21 in the
OVA-treated mice after MCP-5 blockage—in which BAL
eosinophilia was only reduced by 15% but interstitium
eosinophilia was reduced by 87% (Figs. 2 and 3, and Tables
1 and 2)—were decreased by 60%, similar to the BHR
baseline levels detected in PBS-treated littermates (Fig. 4
A). However, BHR was not affected when MCP-5 block-
age was executed at late stages of the inflammatory re-
sponse (day 21), although BAL and interstitium eosino-
philia was comparable to that observed after day 8–day 21
blockage (Fig. 4 B). This indicates that signals delivered by
MCP-5 at early stages of the response could be critical in
the induction of BHR rather than the establishment of
lung inflammation. BHR was decreased by 70% when
MCP-1 was blocked from early stages of the OVA treat-
ment (Fig. 4 A). OVA plus anti–MCP-1–treated mice and
PBS-treated controls show similar degrees of bronchocon-
striction before and after antigen provocation (Fig. 4 A).
The effects of Met-RANTES administration on the devel-
opment of BHR are pronounced and are described in de-
tail elsewhere (31).
Lung Chemokine Expression after Chemokine Blockage.
The in vivo neutralization of eotaxin, MCP-1, or chemo-
kines that bind RANTES receptor(s) either reduces or ab-
rogates the OVA-induced accumulation of one or more
leukocyte types both in BAL and lung interstitium (Figs. 2
and 3, and Tables 1 and 2). This could be related to changes
in the pattern of expression of these chemokines. To evalu-
ate whether eotaxin, MCP-1, or chemokines that bind
RANTES receptor(s) control the expression of themselves
and/or other chemokines, their mRNA expression in the
lung was determined by RPA after the blockage of each
chemokine during OVA treatment. Fig. 5 shows that after
eotaxin neutralization, there was significant expression of
Figure 2. BAL eosinophilia after blockage of chemokines during OVA-induced lung allergic inflammation. Chemokine blockage was performed daily
before OVA provocation on days (d) 8–21. BAL eosinophil accumulation was evaluated 3 h after OVA administration on day 15 (A) or on day 21 (B).
MCP-1, eotaxin, or MCP-5 blockage was also performed after each OVA intranasal challenge for the periods of time indicated on the x-axis, and exclu-
sively analyzed on day 21 (C). Each circle represents a single PBS- or OVA-treated control mouse (open circle) or a single test mouse (filled circle). Bars rep-
resent the mean of each group. Significant difference between control and test groups of mice was determined using the Student’s t test (P ,0.001).
Quantitative data is shown in Table 1 for this and other leukocyte subsets.
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OVA-induced eotaxin, RANTES, and MCP-1 on day 21.
The mRNA expression level of these chemokines was
comparable to those found in OVA-treated controls at the
same time point (Fig. 5). In contrast, eotaxin and RANTES
mRNA expression was reduced significantly in the lung of
Met-RANTES–treated mice at each time point studied
(Fig. 5, and data not shown). MCP-1 expression was not
altered significantly by Met-RANTES in these mice (Fig. 5).
Surprisingly, MCP-1 blockage, which prevents lung accu-
mulation of eosinophils and lymphocytes in response to
OVA, does not prevent the expression of the lymphocytic
and/or eosinophilic chemokines RANTES and eotaxin
(Fig. 5).
Production of Inflammatory Mediators after MCP-1 Blockage.
Since MCP-1 blockage does not affect the mRNA expres-
sion of the chemokines studied, the absence of leukocyte
infiltration in the lung of OVA plus anti–MCP-1–treated
mice could be due to the modulation of activating factors
other than chemokines. These activating factors could be
produced directly by monocytes or induced indirectly by
this subset of leukocytes. Fig. 6 A shows that at 1 h after
OVA administration, the production of LTB4 and PGE2
was increased in the BAL fluid of the OVA-treated mice
on day 21 but not on day 15. However, blockage of MCP-1
completely inhibits OVA-induced production of these two
inflammatory mediators (Fig. 6 A). Similarly, detectable
levels of TXB2 were observed in the BAL fluid of OVA-
treated mice, but not in OVA plus anti–MCP-1–treated
littermates, on day 21 of treatment (Fig. 6 A). No differ-
ences between controls and test mice were detected in
LTC4/D4/E4 levels at the time point analyzed (Fig. 6 A).
The production of IgE in response to OVA was decreased
fivefold in the BAL fluid after MCP-1 blockage at the time
point indicated (Fig. 6 B). Similarly, the production of
Th2-derived cytokines in the same fluid was decreased
fourfold for IL-5 and threefold for IL-4 both on days 15
and 21 (Fig. 6 B). TNF-a production in the BAL fluid was
similar in both groups of mice at both time points (Fig. 6
B). No IFN-g production was detected after OVA or
OVA plus anti–MCP-1 administration at the time points
indicated (Fig. 6 B).
Discussion
We have characterized previously the expression of the
chemokines eotaxin, MCP-5, RANTES, and MCP-1
(mRNA and/or protein), and correlated this with the leu-
kocytes migrating to the lung during a murine model of
lung inflammation (5, 16). From these experiments, we
concluded that MCP-1 mRNA expression paralleled the
accumulation of monocytes/macrophages in this organ,
both events occurring predominantly at early stages of the
Figure 3. OVA-induced lung inflammation after chemokine blockage.
On day 21, lung tissue was excised from OVA-treated mice injected with
control (a), anti–MCP-1 (b), or anti–MCP-5 (c) antibodies. Chemokine
blockage was performed daily before OVA provocation on days 8–21.
One representative mouse out of ten is shown. Quantitative data corre-
sponding to this set of experiments is shown in Table 2.
163 Gonzalo et al.
response (day 15). Also, eotaxin mRNA expression paral-
leled lung eosinophilia predominantly at late stages (day
21). In contrast, other chemokines, such as RANTES or
MCP-5, were expressed throughout the inflammatory re-
action. This underlines the contribution of chemokines at
different stages of the response.
From the work presented here, we first conclude that
eosinophil recruitment and development of BHR in this
model system involve the action of both eosinophilic (eo-
taxin, RANTES, MCP-5, and MIP-1a) and noneosino-
philic chemokines (MCP-1). This indicates the absence of
redundancy, since these chemokines seem to exert a critical
role at different stages and on different pathways of the de-
velopment of OVA-induced lung eosinophilia and BHR.
Thus, MCP-5 recruits practically all the eosinophils present
in the lung airways at early stages of the inflammatory re-
sponse (day 15), while eotaxin attracts .60 and 80% of the
BAL and interstitial eosinophils, respectively, at later stages
of the response (day 21; Fig. 2, A and B, and Tables 1 and
2). In addition, MCP-1 mediates its critical influence
throughout during the development of the inflammatory
response (days 8–21), whereas eotaxin expression is impor-
tant for eosinophil recruitment after each antigen provoca-
tion (Fig. 2, and Tables 1 and 2). MCP-5 also delivers sig-
nals at early stages of the response that are involved in the
establishment of BHR. In fact, blockage of MCP-5 at late
stages does not modify the degree of bronchoconstriction
in response to OVA compared with that observed in the
OVA plus Ab control–treated mice (Fig. 4 A). Further-
more, we also conclude that MCP-5 seems to affect leuko-
cyte traffic through the interstitium, since the accumulation
of these leukocytes in the interstitium—but not in the air-
ways—was severely impaired after MCP-5 blockage (Figs.
2 and 3, and Tables 1 and 2). This could be due to a differ-
ential modulation of adhesion receptors by MCP-5 that re-
sults in retention of the leukocytes in the interstitium. In
fact, it has been demonstrated that chemokines such as eo-
taxin affect the activation state of integrins and their ligandsT
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Table 2. OVA-induced Leukocyte Infiltration in the Lung 
Interstitium after Chemokine Blockage
Chemokine
blockage
Percent decrease in area
covered by infiltrate
Control 0
aEotaxin 90 6 6
aMCP-5 75 6 9
Met-RANTES 73 6 13
MIP-1a 21 6 5
aMCP-1 97 6 23
Lung sections were obtained 3 h after OVA treatment on day 21 (Con-
trol), and the area covered by infiltrate was measured as described in
Materials and Methods. Values after each chemokine blockage are
given as percent decrease from control mice.
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both in vivo and in vitro (37). MCP-5 blockage could also
accelerate the transit of leukocytes from the lung intersti-
tium to the airway spaces by modulating the expression of
other inflammatory mediators. These hypotheses are cur-
rently being investigated in our laboratory.
The use of a RANTES receptor antagonist prevents
completely lung eosinophilia at each time point during
OVA treatment (Fig. 2, and Tables 1 and 2). Our data sug-
gest that RANTES and/or other chemokines that bind
RANTES receptor(s) are key lymphocytic chemokines in
our model, because their blockage impedes pulmonary
lymphocyte accumulation in response to OVA. Although
both MIP-1a and MIP-1b are chemokines able to bind
RANTES receptor(s), only mRNA expression of MIP-1a
is modulated during this OVA model. In a series of elegant
experiments, MIP-1a has been reported to reduce the in-
tensity of the eosinophil recruitment to the lung and air-
ways by 50% during Schistosoma mansoni egg antigen–induced
allergic airway inflammation (38). MIP-1a neutralization
does not affect leukocyte accumulation in the lung at early
stages of the inflammatory response in the particular OVA
model studied here (Fig. 2, and Tables 1 and 2). At late
stages, only a 20% reduction in airway eosinophilia was de-
tected after anti–MIP-1a Ab administration (Fig. 2, and
Table 1). However, lung eosinophilia does not occur in the
absence of CD41 T lymphocytes (5), suggesting that
RANTES receptor(s) may induce lung eosinophilia either
by direct attraction of eosinophils or via the activation and
pulmonary accumulation of CD41 T lymphocytes, or
both. In addition, OVA plus Met-RANTES–treated mice
showed a marked reduction in RANTES and eotaxin
mRNA expression in the lung during OVA treatment (Fig.
5). Thus, RANTES or other as yet unknown chemokines
rather than MIP-1a or MIP-1b act via RANTES recep-
tor(s) and control directly or indirectly the expression of
other chemokines. Therefore, OVA-induced T cell and
eosinophil infiltration in the lung is regulated by RANTES
through itself and eotaxin. However, it is important to note
that the reagent used here, Met-RANTES, may bind to
more than one RANTES receptor and therefore inhibit
the activity of other chemokines. Due to the complexity of
this system, we have reported it in detail elsewhere (31).
Figure 4. Inhibition of OVA-induced airway hyperre-
sponsiveness after chemokine blockage. Results are shown
as the mean 6 SEM for Penh before (gray bars) and after
(black bars) methacholine provocation (n 5 10, two inde-
pendent experiments). Mice were exposed to an aerosol of
methacholine for 1 min, and airway constriction was eval-
uated for the next 5 min. PBS- or OVA plus irrelevant
Ab–treated mice were used as control for OVA-treated lit-
termates in which MIP-1a, eotaxin, MCP-5, or MCP-1
was blocked from days (d) 8 to 21 (A) or at the time points
indicated (B).
Figure 5. Chemokine expres-
sion after chemokine blockage.
On day 21, total RNA from
lungs of OVA plus Ab control–,
OVA plus anti-Eot–, OVA plus
Met-RANTES–, or OVA plus
anti–MCP-1–treated mice was
extracted 3 h after antigen chal-
lenge. Chemokine blockage was
performed daily before OVA
provocation on days 8–21. In a
control group, mice were treated
with PBS (intranasally) and the irrelevant Ab (intravenously) instead of
OVA (intranasally) and the chemokine-neutralizing Ab (intravenously),
respectively. RANTES, eotaxin, and MCP-1 mRNA expression were
determined by RPA. Both TCA and GAPDH mRNA expression were
measured as negative and positive control, respectively. The intensity of
the band for each chemokine was normalized to the intensity of the band
of GAPDH in the control sample (not shown) and analyzed. Chemokine
expression of two representative mice out of four is shown.
Figure 6. Production of OVA-induced mediators of inflammation in
the BAL fluid after MCP-1 blockage. 1 h after OVA administration on
day 15 or 21, inflammatory mediator release was measured in the BAL
fluid of OVA plus irrelevant Ab–treated control mice (open circles) and
OVA plus anti–MCP-1(days 8–21)–treated mice (filled circles). Anti–
MCP-1 or control Abs were administered daily before OVA provocation
on days 8–21. Each circle represents a single mouse. Bars represent the
mean of each group. Significant difference between control and test
groups of mice was determined using the Student’s t test (*P ,0.01).
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Finally, the blockage of the mononuclear phagocyte
chemokine MCP-1 throughout both the induction and
later phases of the response affects these four leukocyte
populations that migrate to the lung in response to OVA as
well as blocking the induction of BHR (Figs. 2, 3, and 4,
and Tables 1 and 2). Monocytes and macrophages are the
first cell types to accumulate during OVA-induced lung in-
flammation in this model (5), and the strongest expression
of MCP-1 occurs at early stages of the inflammatory re-
sponse (Fig. 1; reference 5). Moreover, modification of the
OVA-induced inflammatory response exclusively occurs
when anti–MCP-1 mAb is administered from very early
stages of the inflammatory process (Fig. 2, and Tables 1 and
2). In the absence of MCP-1–mediated signals, there is an
z50% reduction in the number of lung monocytes/mac-
rophages after OVA administration, but interestingly, there
is an almost complete reduction in lymphocyte and eosino-
phil infiltration of the lung (Fig. 2, and Tables 1 and 2).
Taken together, these data suggest that MCP-1 acts up-
stream of the inflammatory process and is a strong candi-
date to regulate the expression of the other chemokines
during this physiological response. Nevertheless, compara-
ble mRNA expression of eotaxin, RANTES, and MCP-1
was detected in the lung of OVA plus anti–MCP-1–treated
mice and OVA-treated controls (Fig. 5). This indicates that
MCP-1 is involved in other regulatory pathways rather
than chemokine expression. Based on our present knowl-
edge of MCP-1 function, it can be hypothesized that the
regulatory pathways are critically affected by the reduction
in monocyte/macrophage numbers after anti–MCP-1
treatment and/or by the depletion of a specific subset of the
cells that is essential for this inflammatory process.
Both lung-resident macrophages distributed along the
airways and circulating macrophages release mediators that
can modulate the function of other cell types and amplify
the lung inflammatory reactions (10, 39). Macrophages can
release eosinophil chemoattractants, including LTB4 (10),
or modulate the generation of LTC4 by eosinophils (12).
They also produce PGE2 and TXB2, which are mediators
of increased vascular permeability. In fact, levels of LTB4,
PGE2, or TXB2 were detectable in the BAL fluid of OVA-
treated mice but greatly diminished in the BAL fluid of
OVA plus anti–MCP-1–treated littermates (Fig. 6 A). This
indicates that the observed production of these factors is
due either to infiltrating cells at this point, to increased acti-
vation of resident cells at late stages of the response, or to a
combination of these two events. LTC4 was not detectable
in the BAL fluid of either group of mice (Fig. 6 A). Mac-
rophages can act as APCs and drive the proliferation of ef-
fector T cells that have been demonstrated to be required
to achieve a functional response. In this scenario, macro-
phage-induced IL-4 production by T cells after antigen
presentation drives the switch in Ig synthesis by B cells to
IgE and potentiates the subsequent priming of mast cells by
IgE plus antigen (40). MCP-1 blockage correlates with a
clear decrease in the BAL levels of IgE and IL-4 after OVA
treatment (Fig. 6 B). Similarly, IL-5 production is also af-
fected by the MCP-1 blockage during OVA-induced lung
allergic inflammation. These results indicate that MCP-1
function(s) (probably through monocyte/macrophage re-
cruitment) are also involved in B and T cell activation. No
IFN-g production was detected in the BAL fluid of test or
control mice, mainly because this model has a predominant
Th2-type response. Macrophages and monocytes also rep-
resent the major source of inflammatory cytokines such as
TNF (39). Despite the fact that only low levels of TNF-a
were detected in the BAL fluid of OVA-treated mice,
MCP-1 blockage reduced these levels by half at the time
point of maximal macrophage and monocyte infiltration in
the lung (day 15; Fig. 6 B).
In conclusion, this paper reports the functional relevance
of chemokines at different stages of a complex inflamma-
tory response in vivo. Chemokines not only ensure the
physical presence of specific leukocytes at the site of in-
flammation by acting directly on them, but also regulate
the expression of other chemokines and the activation of a
variety of inflammatory mediators made by different cell
types. Our results suggest that specific chemokines are in-
volved in different cellular and molecular pathways that in
a coordinated fashion contribute to the complex patho-
physiology of asthma. Understanding all the components
involved in lung allergic inflammation as well as the critical
timing of their actions could represent a crucial step in the
prevention and therapy of this disease. We believe that the
in vivo results presented here may contribute to the support
of clinical applications for the improvement of asthma therapy.
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